New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination

We report a 56-year-old male who developed cutaneous lichen planus (LP) following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination. Multiple topical and systemic therapies were tried with limited success; however, partial improvement was observed with narrow-band UVB (NB-UVB) phototherapy. This r...

Full description

Saved in:
Bibliographic Details
Main Authors: Amira Muftah, Stephen Lee, Mariam Abbas
Format: Article
Language:English
Published: SAGE Publishing 2024-12-01
Series:SAGE Open Medical Case Reports
Online Access:https://doi.org/10.1177/2050313X241307109
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850100894992957440
author Amira Muftah
Stephen Lee
Mariam Abbas
author_facet Amira Muftah
Stephen Lee
Mariam Abbas
author_sort Amira Muftah
collection DOAJ
description We report a 56-year-old male who developed cutaneous lichen planus (LP) following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination. Multiple topical and systemic therapies were tried with limited success; however, partial improvement was observed with narrow-band UVB (NB-UVB) phototherapy. This report adds to the growing evidence of new-onset LP following COVID-19 vaccination and underscores the need for careful reporting, monitoring, and management of vaccine-related adverse effects.
format Article
id doaj-art-8df631b9c4f94e7c981f989a5c7d9ac6
institution DOAJ
issn 2050-313X
language English
publishDate 2024-12-01
publisher SAGE Publishing
record_format Article
series SAGE Open Medical Case Reports
spelling doaj-art-8df631b9c4f94e7c981f989a5c7d9ac62025-08-20T02:40:10ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2024-12-011210.1177/2050313X241307109New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccinationAmira Muftah0Stephen Lee1Mariam Abbas2Department of Dermatology, College of Medicine, University of Calgary, Calgary, AB, CanadaDepartment of Infectious Diseases, College of Medicine, University of Saskatchewan, Regina, SK, CanadaDepartment of Dermatology, College of Medicine, University of Saskatchewan, Regina, SK, CanadaWe report a 56-year-old male who developed cutaneous lichen planus (LP) following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination. Multiple topical and systemic therapies were tried with limited success; however, partial improvement was observed with narrow-band UVB (NB-UVB) phototherapy. This report adds to the growing evidence of new-onset LP following COVID-19 vaccination and underscores the need for careful reporting, monitoring, and management of vaccine-related adverse effects.https://doi.org/10.1177/2050313X241307109
spellingShingle Amira Muftah
Stephen Lee
Mariam Abbas
New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination
SAGE Open Medical Case Reports
title New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination
title_full New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination
title_fullStr New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination
title_full_unstemmed New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination
title_short New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination
title_sort new onset cutaneous lichen planus following vaxzevria oxford astrazeneca covid 19 vaccination
url https://doi.org/10.1177/2050313X241307109
work_keys_str_mv AT amiramuftah newonsetcutaneouslichenplanusfollowingvaxzevriaoxfordastrazenecacovid19vaccination
AT stephenlee newonsetcutaneouslichenplanusfollowingvaxzevriaoxfordastrazenecacovid19vaccination
AT mariamabbas newonsetcutaneouslichenplanusfollowingvaxzevriaoxfordastrazenecacovid19vaccination